In conclusion, our results demonstrate the potential of MOD for synergic treatment with cisplatin to overcome resistance to cisplatin in CRC by modulating epigenetic regulation by KDM1B on the DNA damage repair gene DCLRE1B. This evidence concerns the gene DCLRE1B and colorectal carcinoma.